Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:BCAX NASDAQ:LNTH NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$14.69+2.3%$15.96$13.50▼$25.67$3.43B0.473.21 million shs2.90 million shsBCAXBicara Therapeutics$16.26-10.9%$13.40$7.80▼$28.09$996.68MN/A701,057 shs2.41 million shsLNTHLantheus$56.60+1.8%$53.92$47.25▼$118.21$3.78B0.091.73 million shs1.30 million shsMIRMMirum Pharmaceuticals$73.03-0.7%$72.72$36.88▼$78.54$3.69B0.81780,594 shs364,581 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+2.30%+0.96%-7.67%-13.84%-6.91%BCAXBicara Therapeutics-10.90%-12.16%+55.75%+42.01%-25.96%LNTHLantheus+1.80%+3.68%+12.28%-21.76%-51.50%MIRMMirum Pharmaceuticals-0.68%+1.19%-1.82%+39.93%+85.07%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$14.69+2.3%$15.96$13.50▼$25.67$3.43B0.473.21 million shs2.90 million shsBCAXBicara Therapeutics$16.26-10.9%$13.40$7.80▼$28.09$996.68MN/A701,057 shs2.41 million shsLNTHLantheus$56.60+1.8%$53.92$47.25▼$118.21$3.78B0.091.73 million shs1.30 million shsMIRMMirum Pharmaceuticals$73.03-0.7%$72.72$36.88▼$78.54$3.69B0.81780,594 shs364,581 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+2.30%+0.96%-7.67%-13.84%-6.91%BCAXBicara Therapeutics-10.90%-12.16%+55.75%+42.01%-25.96%LNTHLantheus+1.80%+3.68%+12.28%-21.76%-51.50%MIRMMirum Pharmaceuticals-0.68%+1.19%-1.82%+39.93%+85.07%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$27.6788.34% UpsideBCAXBicara Therapeutics 2.75Moderate Buy$31.8695.93% UpsideLNTHLantheus 2.50Moderate Buy$74.5031.63% UpsideMIRMMirum Pharmaceuticals 3.00Buy$79.709.13% UpsideCurrent Analyst Ratings BreakdownLatest BCAX, LNTH, MIRM, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025MIRMMirum PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $81.0010/14/2025BCAXBicara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LNTHLantheusThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$110.00 ➝ $77.0010/8/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025LNTHLantheusThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$110.00 ➝ $77.0010/8/2025LNTHLantheusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Buy (B-)9/27/2025BCAXBicara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LNTHLantheusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M8.22$0.55 per share26.53$1.48 per share9.93BCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/ALNTHLantheus$1.53B2.51$7.22 per share7.84$15.65 per share3.62MIRMMirum Pharmaceuticals$336.89M10.89N/AN/A$4.70 per share15.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8617.0821.29N/A44.06%41.01%28.47%11/6/2025 (Estimated)BCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)LNTHLantheus$312.44M$3.7615.058.97N/A17.82%34.06%19.10%11/5/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)Latest BCAX, LNTH, MIRM, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BCAXBicara Therapeutics-$0.55N/AN/AN/AN/AN/A11/11/2025Q3 2025MIRMMirum Pharmaceuticals-$0.11N/AN/AN/A$130.11 millionN/A11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A11/5/2025Q3 2025LNTHLantheus$1.28N/AN/AN/AN/AN/A8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.215.332.78BCAXBicara TherapeuticsN/A25.8025.80LNTHLantheus0.494.294.07MIRMMirum Pharmaceuticals1.213.132.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%BCAXBicara TherapeuticsN/ALNTHLantheus99.06%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%BCAXBicara TherapeuticsN/ALNTHLantheus2.00%MIRMMirum Pharmaceuticals22.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.63 million229.80 millionOptionableBCAXBicara Therapeutics3254.61 millionN/AN/ALNTHLantheus70067.99 million66.63 millionOptionableMIRMMirum Pharmaceuticals14050.24 million38.75 millionOptionableBCAX, LNTH, MIRM, and ADMA HeadlinesRecent News About These CompaniesQ3 EPS Forecast for Mirum Pharmaceuticals Raised by AnalystOctober 19 at 2:10 AM | americanbankingnews.comEquities Analysts Set Expectations for MIRM FY2026 EarningsOctober 18 at 3:01 AM | americanbankingnews.comLeerink Partnrs Has Optimistic Outlook of MIRM Q3 EarningsOctober 17, 2025 | marketbeat.comMorgan Stanley Maintains Mirum Pharmaceuticals (MIRM) Overweight RecommendationOctober 17, 2025 | msn.comMirum Pharmaceuticals price target raised to $81 from $75 at Morgan StanleyOctober 16, 2025 | msn.comWhat is Leerink Partnrs' Estimate for MIRM FY2026 Earnings?October 16, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $76.50 Consensus Price Target from BrokeragesOctober 16, 2025 | americanbankingnews.comWill Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?October 14, 2025 | zacks.comOak Ridge Investments LLC Invests $922,000 in Mirum Pharmaceuticals, Inc. $MIRMOctober 13, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Time to Buy?October 11, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by AnalystsOctober 11, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from AnalystsOctober 11, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 6.9% - Should You Buy?October 10, 2025 | marketbeat.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2025 | businesswire.comMirum Pharmaceuticals' (MIRM) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Wealth Enhancement Advisory Services LLCOctober 5, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Upgraded at Wall Street ZenSeptember 26, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Raised to Strong-Buy at TD CowenSeptember 26, 2025 | marketbeat.comMirum draws new Buy at TD Cowen on growth prospectsSeptember 26, 2025 | msn.comTD Cowen Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy RecommendationSeptember 25, 2025 | msn.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Voya Investment Management LLCSeptember 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAX, LNTH, MIRM, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$14.69 +0.33 (+2.30%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$14.67 -0.02 (-0.16%) As of 04:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Bicara Therapeutics NASDAQ:BCAX$16.26 -1.99 (-10.90%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$16.08 -0.19 (-1.14%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Lantheus NASDAQ:LNTH$56.60 +1.00 (+1.80%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$55.71 -0.89 (-1.57%) As of 04:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$73.03 -0.50 (-0.68%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$73.00 -0.03 (-0.04%) As of 10/20/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
